期刊文献+

帕金森病小鼠前庭神经核内谷氨酸和谷氨酸受体1的表达 被引量:1

Expression of Glutamate and Glutamate Receptor-1 in the Vestibular Nucleus of Mice with Parkinson's Disease
下载PDF
导出
摘要 目的研究帕金森病(PD)小鼠前庭神经核内谷氨酸(Glu)及其谷氨酸受体(GluR1)的表达。方法采用免疫细胞化学技术检测帕金森病小鼠前庭神经核内Glu及GluR1的表达,利用透射电镜技术检测前庭神经核内神经元超微结构的改变。结果与对照组相比,在PD小鼠前庭神经核内Glu表达增加(P<0.01),同时GluR1表达减少(P<0.01)。透射电镜的结果显示前庭神经核内神经元超微结构呈病理性改变:神经元线粒体肿胀变性、嵴消失、呈空泡状改变,粗面内质网(RER)扩张,星形胶质细胞呈增生状改变。结论PD小鼠前庭神经核内的Glu及GluR1在神经元内表达的变化及其超微结构的改变,推测其变化与临床运动障碍、平衡失调有一定关系,为帕金森病的临床治疗提供了可靠的形态学依据。 Objective To investigate the expression of glutamate and glutamate receptor-1 in vestibular nucleus of mouse model of Parkinson's disease. Methods The distribution of glutamate and glutamate receptor-1 was observed with immunohistochemistry;meanwhile transmission electron microscopy was used to detect ultrastructural changes of neurons in the vestibular nucleus. Results Compared with the control group, Glu expression level was higher in vestibular nucleus but GluR1 expression level was lower in vestibular nucleus in the group of Parkinson's disease. What's more, transmission electron microscopy showed that the ultrastructure of neurons was partially damaged, which included swelling and partial vacuoles of mitochondria, dilation of granular endoplasmic reticulum, and hyperplasia of astrocytes. Conclusion The expression of Glu and its receptor-1 in the vestibular nucleus of the PD model,which we speculate has a certain relation with clinical dyskinesia and dysbalance, provides a reliable basis for the further study of the morphology of Parkinson's disease.
出处 《中国医科大学学报》 CAS CSCD 北大核心 2008年第2期181-183,共3页 Journal of China Medical University
基金 辽宁省教育厅高等学校科研基金资助项目(2004D106)
关键词 帕金森病 前庭神经核 谷氨酸 谷氨酸受体1 Parkinson's disease vestibular nucleus glutamate glutamate receptor-1
  • 相关文献

参考文献8

  • 1POPPER P,RODROGO JP,ALVAREZ JC,et al.Expression of the AMPA-selective receptor subunits in the vestibular nuclei of the chinchilla[J].Brain Res Mol Brain Res,1997,44(1):21-30.
  • 2EMBORG ME,TETRUD JW,MOIRANO J,et al.Rest tremor inrhesus monkeys with MPTP-induced parkinsonism[J].Front Biosci,2003,8(2):148-154.
  • 3PRZEDBORSKI S,VILA M.Thel-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model:a tool to explore the pathogenesis of Parkinson's disease[J].Ann NY Acad Sci,2003,991 (1):189-198.
  • 4STAAL RG,HOGAN KA,LIANG CL,et al.In vitro studies of striatal vesicles containing the vesicular monoamine transporter(VMAT2):rat versus mouse differences in sequestration of 1-methy-4-phenylpyridinium[J].J Pharmacol Exp Ther,2000,293 (2):329-335.
  • 5DI MONTE DA,ROYLAND JE,IRWIN I,et al.Astrocytes as the sitefor bioactivation of neurotoxins[J].Neurotoxicology,1996,17 (3-4):697-703.
  • 6BLANDINI F,GREENAMYRE JT.Prospects of glutamate antagonists in the therapy of Parkinson's disease[J].Fundam Clin Pharmacol,1998,12(1):4-12.
  • 7REISEI D,BANNERMAN DM,SCHMITr WB,et al.Spatial memory dissociations in mice lacking GluR1[J].Nat Neuresci,2002,5(9):868-873.
  • 8PELLEGRINI-GIAMPIETRO DE,PULSINELLI WA,ZUKIN RS.NMDA and non-NMDA receptor gene expression following global brain ischemia in rats:effect of NMDA and non-NMDA receptor antagonists[J].J Neurechem,1994,62(3):1067-1073.

同被引文献10

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部